- Meningococcal Conjugate Vaccines
- Meningococcal Polysaccharide Vaccine
- Serogroup B Meningococcal Vaccine
Meningococcal Vaccine Market size was valued at USD 2.77 billion in 2022 and is expected to reach USD 5.92 billion in 2029, growing at a CAGR of 9.14% from 2022 to 2029. Meningococcal disease is a fatal disease caused by a bacteria called as Neisseria Meningitides which cause potential infection in the meninges, the thin layers of connective tissues which surrounds spinal cord and brain. Common symptoms are bacteremia, pneumonia and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes and lethargy. Surge in incidence of meningococcal disease is expected to play vital role in growth of the global meningococcal vaccines market. Meningococcal meningitis is a major public health concern. Various treatment approaches with reasonable costs have been established, however they continue to result in a high fatality rate. In newborns and young children, they can have long-term neurological repercussions. According to a WHO estimate, 50 percent of meningitis cases occur in children under the age of five. The next susceptible age group is 15-19 years. Meningitis has had such a negative impact on humanity that various multinational private agencies have stepped up to create a vaccine. Meningococcal vaccines are available in four different categories. Meningitis A (MenA) and three Conjugate MenACWY vaccines are available. Furthermore, growing awareness among the people regarding the seriousness of disease, government initiatives, increase R&D investments by various players, introduction of advanced vaccines are expected to boost growth of the meningococcal vaccines market. However, lack of awareness, high cost of vaccines, unfavourable regulatory conditions are restrains of global meningococcal vaccines market.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Rise in incidence and mortality rate of meningococcal disease is expected to create lucrative growth opportunities for the global market. Favourable government initiatives are expected create awareness among people. For example, by 2018 Men conjugate vaccines programmes in Africa is anticipated to prevent around 1, 23, 000 deaths. Meningococcal vaccine market is high consolidated market with very few market players. It is experiencing at rapid growth due to new products and it is expected to experience tremendous growth due to new entrants into the market during the forecast period.
The meningococcal vaccines market size was valued at USD 2.77 billion in 2022
The meningococcal vaccines market key players are: GlaxoSmithKline plc. (UK) JN-International Medical Corporation (U.S.) Novartis International AG (Switzerland) Sanofi (France) Pfizer, Inc. (U.S.) Baxter International, Inc. (U.S.)
The meningococcal vaccines market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
1. Executive Summary |
2. Global Meningococcal Vaccines Market Introduction |
2.1.Global Meningococcal Vaccines Market - Taxonomy |
2.2.Global Meningococcal Vaccines Market - Definitions |
2.2.1. Type |
2.2.2.End User |
2.2.3.Region |
3. Global Meningococcal Vaccines Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID-19 on Market |
4. Global Meningococcal Vaccines Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Meningococcal Vaccines Market By Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Meningococcal Conjugate Vaccines |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Meningococcal Polysaccharide Vaccine |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Serogroup B Meningococcal Vaccine |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6. Global Meningococcal Vaccines Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Hospitals |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Clinic |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Others |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7. Global Meningococcal Vaccines Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8. North America Meningococcal Vaccines Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Meningococcal Conjugate Vaccines |
8.1.2.Meningococcal Polysaccharide Vaccine |
8.1.3.Serogroup B Meningococcal Vaccine |
8.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospitals |
8.2.2.Clinic |
8.2.3.Others |
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9. Europe Meningococcal Vaccines Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Meningococcal Conjugate Vaccines |
9.1.2.Meningococcal Polysaccharide Vaccine |
9.1.3.Serogroup B Meningococcal Vaccine |
9.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospitals |
9.2.2.Clinic |
9.2.3.Others |
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
9.3.6.Rest of EU |
10. Asia Pacific (APAC) Meningococcal Vaccines Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Meningococcal Conjugate Vaccines |
10.1.2.Meningococcal Polysaccharide Vaccine |
10.1.3.Serogroup B Meningococcal Vaccine |
10.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospitals |
10.2.2.Clinic |
10.2.3.Others |
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11. Middle East and Africa (MEA) Meningococcal Vaccines Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Meningococcal Conjugate Vaccines |
11.1.2.Meningococcal Polysaccharide Vaccine |
11.1.3.Serogroup B Meningococcal Vaccine |
11.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospitals |
11.2.2.Clinic |
11.2.3.Others |
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12. Latin America Meningococcal Vaccines Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Meningococcal Conjugate Vaccines |
12.1.2.Meningococcal Polysaccharide Vaccine |
12.1.3.Serogroup B Meningococcal Vaccine |
12.2. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospitals |
12.2.2.Clinic |
12.2.3.Others |
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.GlaxoSmithKline plc. (UK) |
13.2.2.JN-International Medical Corporation (U.S.) |
13.2.3.Novartis International AG (Switzerland) |
13.2.4.Sanofi (France) |
13.2.5.Pfizer, Inc. (U.S.) |
13.2.6.Baxter International, Inc. (U.S.) |
14. Research Methodology |
15. Appendix and Abbreviations |